Stock Analysis
BioNeutra Global Third Quarter 2023 Earnings: CA$0.03 loss per share (vs CA$0.027 loss in 3Q 2022)
BioNeutra Global (CVE:BGA) Third Quarter 2023 Results
Key Financial Results
- Revenue: CA$2.53m (down 23% from 3Q 2022).
- Net loss: CA$1.34m (loss widened by 8.5% from 3Q 2022).
- CA$0.03 loss per share (further deteriorated from CA$0.027 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioNeutra Global's share price is broadly unchanged from a week ago.
Risk Analysis
Before we wrap up, we've discovered 4 warning signs for BioNeutra Global that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if BioNeutra Global might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:BGA
BioNeutra Global
Engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products, with a focus on oligosaccharides.